Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
NCT03025035Phase 2Completed
- Sponsor
- Yuanyuan Biotech
- Start
- Sep 2017
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in breast cancer, sponsored by Yuanyuan Biotech. Primary endpoint: Overall Response Rate up to 2 years. Started Sep 2017; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03025035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025035.